Scientists have shown that the removal of non-dividing senescent cells, which are normally associated with aging, also appears to prevent Type 1 diabetes in diabetic mouse strains.
Clearing senescent beta cells prevents T1 diabetes
Type 1 diabetes (T1D) is a chronic condition in which the pancreas produces little or no insulin. Insulin is a hormone that allows sugar (glucose) to enter cells in order to create energy, so it is critical to cellular function and life.
This platform was applied for the first time in our newly released Longevity Industry in Singapore report, utilizing data on the companies, investors, research labs and non-profit organizations featured in the report.
Aging Analytics Agency is planning to implement a number of updates, additions and enhancement for this platform in the coming months, including interactive and filterable mindmaps, infographics and network diagrams illustrating connections and interactions within the global Longevity Industry, as well as additional features, to be introduced throughout 2019.
Link to Platform: http://mindmaps.aginganalytics.com/
Samsara Therapeutics has completed a seed financing round in collaboration with Apollo Ventures, a venture capital company and biotech incubator that supports longevity research and treatments for age-related diseases.
Samsara Therapeutics, Inc. (“Samsara,”) a platform biotechnology startup engaged in the discovery and development of compounds that address the primary molecular causes of aging, announced today the closing of a seed financing round. The financing was led by Apollo Ventures, a life sciences venture capital firm and company builder working across Europe and North America.
Additionally, on February 19th, 2019 Nature Communications published a peer-reviewed paper, “The flavonoid 4,4′-dimethoxychalcone promotes autophagy-dependent longevity across species” authored by Samsara’s scientific team [1]. The paper demonstrates the capability of the Samsara platform to identify novel MoA geroprotective small molecules that extend healthy lifespan across species and which are protective in mammalian models of disease.
Late last year, archaeologists in China found some very interesting items in an ancient tomb dating back as far as 202 BC, including a bronze vessel that somehow still held liquid. The liquid, which at the time was thought to be some type of wine, has since undergone closer examination that reveals its true purpose.
China’s Xinhua news agency is now reporting that the beverage was actually an “elixir of immortality” that matches descriptions from ancient documents. The substance has been tested and, if scientists are right about it, there’s probably little chance it would do anything to extend someone’s life, and may even usher death in even quicker.
The role of epigenetics, which determine how your genes are expressed, is being increasingly implicated in aging, as is the potential of therapies that revert epigenetics back to those of a younger person.
What are epigenetic alterations?
The DNA in each of our cells is identical, with only some small variations, so why do our various organs and tissues look so different, and how do cells know what to become?
The longevity sector is showing signs of being taken more seriously. On Tuesday, Mehmood Khan, vice chairman and chief scientific officer of PepsiCo, announced he’s joining Life Biosciences, a startup dedicated to “age-reversal.” Khan will become the startup’s CEO and a member of its board of directors.
Aubrey de Grey is getting more bullish about his timeframes for robust human rejuvenation and longevity escape velocity. He now thinks it is only 18 years away and not 25 years anymore.
There is fastly progressing science and there is a rapid increase in funding and formation of companies. Areas that were making slow progress like Mitosens are now rapidly progressing. Cross-linking is making progress as well.
Robust mouse rejuvenation could be only 3 years away instead of five years. Robust mouse rejuvenation could be by 2022.
